Recent 8-K filings for PEN

• May 7, 2026, 7:59 PM ET M&A materiality 0.90 positive item 5.07

  Penumbra shareholders approve merger with Boston Scientific; vote 28.6M for, 85k against

  Special meeting held May 6, 2026; 28,665,933 shares present, quorum achieved.

• May 6, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Penumbra Q1 revenue $374.8M (+15.6% YoY); net income $32.6M; no guidance due to pending BSX acquisition

  Revenue $374.8M, up 15.6% YoY; thrombectomy $253.9M (+12.1%), embolization & access $120.8M (+23.8%).

• February 25, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Penumbra Q4 revenue $385.4M (+22.1%); operating income $59.2M; FY25 rev $1.4B (+17.5%)

  Revenue $385.4M for Q4, up 22.1% YoY (20.9% constant currency). US Thrombectomy $203.1M (+12.4%).

• January 15, 2026, 6:59 PM ET M&A materiality 1.00 positive item 1.01item 2.02item 7.01item 9.01 ◈ Material Agreements

  Boston Scientific to acquire Penumbra: $374 cash or 3.8721 BSX shares per share; 73% cash/27% stock

  Penumbra holders elect $374 cash or 3.8721 BSX shares per share; proration targets 73.26% cash/26.74% stock.

• November 5, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Penumbra Q3 revenue $354.7M (+17.8% YoY); full-year guidance raised to $1.375-1.380B

  Net income of $45.9M; adjusted EBITDA $66.7M (18.8% margin).

• August 27, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  Penumbra promotes Shruthi Narayan to President, CEO remains Elsesser

  Shruthi Narayan, former President Interventional, becomes President effective Sept 1, 2025; reports to CEO Adam Elsesser.

• July 29, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Penumbra Q2 revenue $339.5M (+13.4% YoY); net income $45.3M vs prior-year loss

  Revenue $339.5M, +13.4% YoY; U.S. Thrombectomy $188.5M (+22.6%); U.S. VTE +42%.

• April 23, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Penumbra Q1 2025 revenue $324.1M (+16.3% YoY); net income $39.2M; raises U.S. thrombectomy guidance

  Revenue $324.1M (+16.3% YoY); U.S. Thrombectomy $187.9M (+25.0%).

• February 18, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Penumbra Q4 adjusted revenue $321.3M (+13%); U.S. thrombectomy up 27%

  Adjusted revenue (excl. Italian payback) Q4 $321.3M, up 12.9% YoY; reported revenue $315.5M (+10.8%).

• October 30, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Penumbra Q3 revenue $301M (+11.1% YoY); U.S. thrombectomy up 21.2%; raises segment guidance

  Revenue $301.0M, +11.1% YoY; net income $29.5M; adjusted EBITDA $56.7M (18.8% margin).

• August 13, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Penumbra announces $200M share repurchase authorization, $100M accelerated buyback

  Board authorized up to $200M in stock repurchases through July 31, 2025.

• July 30, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Penumbra Q2 revenue $299.4M (+14.5%); loss from ops $81M on $110.3M impairment charges

  U.S. thrombectomy revenue $153.7M, up 24.9% YoY; global thrombectomy revenue $203.5M (+25.2%).

• May 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Penumbra Q1 revenue $278.7M (+15.4% YoY); U.S. thrombectomy up 35.2%; reaffirms FY24 guidance

  Revenue $278.7M, up 15.4% YoY (15.2% constant currency); U.S. thrombectomy $150.3M, +35.2%.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.75 · Most common event earnings

11 positive 0 negative 6 neutral

source · PEN on sec.gov